Aims and Scope of Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs is a monthly peer-reviewed medical journal covering developments in pharmaceutical research, from animal studies through to early clinical investigation. The journal's scope includes therapeutics in many areas: pulmonary-allergy, dermatology, gastrointestinal, arthritis, infectious disorders, endocrine and metabolic, central and peripheral nervous system, cardiovascular and renal, and oncology. Less
Key Metrics
CiteScore 

8.6
H-Index 

114
Impact Factor 

5 - 10
SJR 

Q1Pharmacology

SNIP 

1.06
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1994 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Opinion on Investigational Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Opinion on Investigational Drugs
Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.
- 1 Jul 2026
- Expert opinion on investigational drugs
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights
- 27 Jun 2026
- Expert Opinion on Investigational Drugs
Odronextamab: a bispecific antibody for follicular lymphoma
- 26 Jun 2026
- Expert Opinion on Investigational Drugs
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
- 18 Jun 2026
- Expert Opinion on Investigational Drugs
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
- 18 Jun 2026
- Expert Opinion on Investigational Drugs
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
- 12 Jun 2026
- Expert Opinion on Investigational Drugs
Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.
- 1 Jul 2026
- Expert opinion on investigational drugs
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights
- 27 Jun 2026
- Expert Opinion on Investigational Drugs
Odronextamab: a bispecific antibody for follicular lymphoma
- 26 Jun 2026
- Expert Opinion on Investigational Drugs
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
- 18 Jun 2026
- Expert Opinion on Investigational Drugs
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
- 18 Jun 2026
- Expert Opinion on Investigational Drugs
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
- 12 Jun 2026
- Expert Opinion on Investigational Drugs